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ABSTRACT	
Background	
Huntington’s	disease	(HD)	is	an	autosomal	dominant,	neurodegenerative	movement	
disorder,	typically	characterized	by	chorea.	Dystonia	is	also	recognised	as	part	of	the	HD	
motor	phenotype,	although	little	work	detailing	its	prevalence,	distribution,	severity	and	
impact	on	functional	capacity	has	been	published	to	date.	
	
Methods	
Patients	(>18	years)	were	recruited	from	the	Cardiff	(United	Kingdom)	HD-clinic,	each	
undergoing	a	standardised	videotaped	clinical	examination	and	series	of	functional	
assessment	questionnaires	(Unified	Huntington’s	Disease	Rating	Scale	(UHDRS),	Burke-Fahn-
Marsden	Dystonia	Rating	Scale	(BFMDRS)	and	modified	version	of	the	Toronto	Western	
Spasmodic	Torticollis	Rating	Scale.	The	presence	and	severity	of	dystonia	was	scored	by	four	
independent	neurologists	using	the	BFMDRS	and	the	UHDRS	rating	scales.	Statistical	analysis	
included	Fisher’s	exact	test,	Wilcoxon	test,	ANOVA	and	calculation	of	correlation	coefficients	
where	appropriate.	
	
Results	
Forty-eight	(91%	(48/53)	demonstrated	evidence	of	dystonia,	with	the	highest	prevalence	in	
the	left	upper	limb	(n=44,	83%),	right	upper	limb	most	severely	affected,	and	eyes	least	
affected.	Statistically	significant	positive	correlations	(p<0.05)	were	observed	between	
dystonia	severity	and	increasing	HD-disease	stage	and	motor	disease	duration.	Deterioration	
in	functional	capacity	also	correlated	with	increasing	dystonia	severity.	No	significant	
relationship	was	observed	with	age	at	motor	symptom	onset	or	CAG-repeat	length.	
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Conclusions	
We	report	a	high	prevalence	of	dystonia	in	adult	HD	patients,	with	worsening	dystonia	
severity	with	increasing	HD-disease	stage	and	motor	disease	duration.	The	recognition	and	
management	of	dystonic	symptoms	in	routine	clinical	practice	will	aid	overall	symptomatic	
treatment,	and	aid	functional	improvement.		
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INTRODUCTION	
Huntington’s	disease	(HD)	is	an	autosomal	dominant,	neurodegenerative	disorder	
characterized	by	disorders	of	movement,	cognition	and	behaviour,	and	caused	by	a	
trinucleotide	(CAG)	repeat	expansion	in	the	huntingtin	(HTT)	gene.[1]	Chorea	is	the	most	
widely	recognised	type	of	movement	disorder	associated	with	HD,	although	dystonia,	
tremor,	myoclonus,	ataxia	and	tics	are	also	recognised.[2-4]	Dystonia	involves	loss	of	co-
ordinated	contraction	of	antagonistic	muscle	groups,	altering	muscle	tone	and	leading	to	
abnormal	movement	and	postures.[5]	Few	previous	studies	have	sought	to	characterise	
dystonia	in	patients	with	HD,	with	those	that	have	tending	to	involve	clinical	descriptions	of	
smaller	cohorts.[6]	Several	groups	have	observed	that	dystonia	appears	most	prominent	in	
those	with	juvenile	HD	(onset	<20	years)	and	longer	CAG	repeat	length,	while	others	have	
noted	a	positive	correlation	between	dystonia	severity	and	motor	disease	duration.[7,	8]	In	
spite	of	this,	dystonia	remains	difficult	to	assess	in	the	presence	of	chorea,	and	tends	to	be	
overlooked	in	HD	in	favour	of	treating	the	chorea.		
	
Dystonia	is	widely	considered	to	be	a	neuronal	circuit	disorder	involving	the	basal	ganglia,	
striatum,	cerebellum,	and	motor	cortices.[9]	The	exact	nature	of	this	disruption	remains	
poorly	understood	but	is	likely	to	involve	altered	monoaminergic	neurotransmission,	
impacting	functional	connectivity	between	selected	brain	regions.	Striatal	atrophy	is	a	
prominent	feature	of	HD	pathogenesis	with	recent	work	identifying	preferential	loss	of	
parvalbuminergic	(PARV+)	interneurons	contributing	to	the	dystonia	phenotype.[10]	An	
improved	characterisation	of	dystonia	in	HD	may	aid	in	improving	our	understanding	of	the	
mechanisms	that	give	rise	to	distinct	clinical	phenotypes.	
	
Characterisation	of	Dystonia	in	Huntington’s	Disease	
van	de	Zande	et	al	
	
	
5	
This	study	involves	the	largest	cohort	of	genetically	confirmed	HD	patients	to	undergo	
systematic	and	standardised	assessment	of	the	rate,	distribution	and	severity	of	dystonia.	
We	have	sought	to	identify	potential	clinical	markers	associated	with	the	presence	and	
severity	of	dystonia,	whether	CAG	repeat	length	correlates	with	dystonic	symptoms,	and	
how	dystonia	may	impact	on	an	individual’s	functional	capacity.		
	
METHODS	
Participants	>18	years	of	age	with	a	confirmed	pathogenic	CAG	expansion	(>39	repeats)	in	
the	HTT	gene,	were	invited	to	participate	in	the	study,	via	the	South	Wales	HD	Service	(May-
October	2016).		All	participants	provided	informed	consent	or	third	party	assent	where	
appropriate	(‘Move	Wales:	Welsh	Movement	Disorders	Research	Network	REC	Ref:	
14/WA/0017).		
	
Clinical	Data	Collection	
Baseline	clinical	data	collection	included	HD	disease	stage,	age	at	motor	symptom	onset,	
past	and	present	medication	and	CAG	repeat	length.	HD	disease	stage	was	determined	by	
the	physician	at	their	most	recent	clinical	consultation,	principally	determined	by	functional	
ability.[11]	Participants	underwent	a	standardised	videotaped	clinical	examination	using	a	
modified	form	of	the	Burke-Fahn-Marsden	Dystonia	Rating	Scale	protocol	(BFMDRS),	a	series	
of	functional	capacity	questionnaires	including	the	Unified	Huntington’s	Disease	Rating	Scale	
(UHDRS),	BFMDRS	functional	capacity	questionnaire	and	a	modified	version	of	the	Toronto	
Western	Spasmodic	Torticollis	Rating	Scale	(Disability	Section)	(TWSTRS).[12-14]	A	question	
from	the	Abnormal	Involuntary	Movement	Scale	(AIMS)	was	used	to	determine	participant	
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awareness	of	dystonia.[15]	Distribution	of	chorea	was	determined	from	that	observed	
during	the	videotaped	clinical	examination.	
	
Assessment	of	Videotaped	Clinical	Examination	
The	videotaped	examinations	were	reviewed	by	four	independent	neurologists,	each	with	
expertise	in	movement	disorders	and	use	of	the	UHDRS	and	BFMDRS	rating	scales,	and	
blinded	to	all	clinical	information	other	than	the	genetic	diagnosis	of	HD.	Each	reviewer	was	
given	detailed	written	instructions	of	how	to	apply	the	rating	scales,	and	an	opportunity	to	
review	the	standardised	UHDRS	and	BFMDRS	videotaped	clinical	examinations.	Each	
videotaped	examination	was	scored	using	the	UHDRS	dystonia	section	(maximum	score	20)	
and	BFMDRS	(maximum	score	120).	The	UHDRS	Dystonia	scale	is	subdivided	into	five	body	
regions	(trunk,	right	and	left	upper	and	lower	limbs)	each	scored	between	0	and	4,	while	the	
BFMDRS	scores	severity	and	provoking	factors	in	nine	body	regions	(eyes,	face,	speech	and	
swallow,	neck,	trunk,	right	and	left	upper	and	lower	limbs)	each	being	score	between	0	and	
16.	The	sum	of	scores	for	each	rating	scale	was	calculated	per	neurologist,	and	the	mean	of	
this	value	used	for	further	analysis.	Dystonia	was	considered	to	be	present	in	an	individual	
region	when	three	or	more	of	the	scoring	neurologists	noted	its	presence.		
	
Statistical	Analysis	
Statistical	analysis	involved	use	of	the	R	statistical	software	package	with	Fisher’s	exact	test,	
ANOVA,	Pearson’s	correlation	coefficients,	normal	regression	and	Wilcoxon	signed	rank	test	
calculations	used	where	appropriate.	The	interclass	correlation	coefficient	(ICC)	was	used	to	
determine	the	inter-rater	reliability	between	clinicians	and	the	intra-reliability	of	two	raters	
re-scoring	10	of	the	original	videos	after	an	interval	of	8	weeks.		A	p-value	<0.05	was	
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considered	to	be	significant.	
	
RESULTS	
Fifty-three	symptomatic	and	pre-manifest	patients	(32M:	21F),	with	genetically	confirmed	
HD	were	recruited.	Median	age	at	examination	was	49	years	(range:	24-78	years)	with	a	
mean	duration	of	motor	symptoms	of	5.93	years.	Eight	patients	(15.1%)	were	receiving	
treatment	with	neuroleptic	medication	at	the	time	of	assessment,	with	two	further	
individuals	having	taken	this	form	of	medication	in	the	past.	There	was	no	reported	
temporal	relationship	between	the	onset	of	dystonia	and	use	of	neuroleptic	medication,	and	
no	clinical	evidence	of	tardive	dyskinesia.	Information	relating	to	HTT	CAG	repeat	length	was	
available	in	50	participants	with	a	mean	length	of	43	repeats	(standard	deviation:	2.73).	
Genetic	testing	in	the	remaining	three	was	performed	elsewhere	and	although	confirmed	to	
involve	a	pathogenic	CAG	expansion,	the	exact	number	of	repeats	was	unknown.	A	summary	
of	the	principal	demographic	characteristics	can	be	seen	in	Table	1.		
	
Dystonia	was	identified	in	at	least	one	body	region	in	91%	of	patients	(48/53).	Of	the	five	
individuals	considered	not	to	have	any	evidence	of	dystonia,	three	or	more	of	the	raters	
agreed	that	there	was	evidence	of	dystonia	but	not	to	its	distribution.	Excluding	these	five	
patients,	the	most	commonly	affected	body	regions	were	the	Left	(44/48,	83%)	and	Right	
(41/48,	77%)	Upper	Limbs.	Overall	mean	dystonia	severity	score	was	32.18	(standard	
deviation:	28.21)	using	the	BFMDRS,	and	7.57	(standard	deviation:	4.92)	using	the	UHDRS.	
Dystonia	severity	was	most	marked	in	the	Upper	Limbs	using	the	BFMDRS	(mean	scores:	
Right	(5.42),	Left	(5.39)),	and	in	the	trunk	(including	the	cranio-facial	region)	(mean	score:	
1.76)	using	the	UHDRS.	Using	the	recently	updated	dystonia	classification	system,	a	
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generalized	dystonia	distribution	was	most	commonly	observed	(n=32),	followed	by	
multifocal	(n=10),	segmental	(n=4)	and	focal	(n=2)	forms.[16]		
	
Evaluation	of	the	inter-rater	reliability	scores	was	considered	excellent	(inter-rater	reliability	
ICC	of	0.91	(UHDRS)	and	0.95	(BFMDRS)).	Test-Rest	evaluation	determined	ICC	values	of	0.81	
and	0.96	(UHDRS)	and	0.94	and	0.98	(BFMDRS)	(Supplementary	Table	1).	The	mean	values	
and	variance	for	each	rater	can	be	seen	in	Supplementary	Figures	2	and	3.	Agreement	
between	three	of	the	four	raters	was	allowed	as	confirmation	of	the	presence	of	dystonia	in	
each	case,	although	agreement	between	all	four	raters	was	seen	in	the	majority	of	cases	
(47/53	(89%)).		
	
Evaluation	of	dystonia	severity	with	respect	to	HD	disease	stage	demonstrated	a	gradual	
increase	in	mean	dystonia	severity	scores	from	premanifest	to	late	stages	(Table	1	and	
Figure	1).	Further	analysis	found	a	significant	increase	in	dystonia	severity	between	each	
stage	using	both	standardised	tools,	BFMDRS	(p-value:	<2e-16)	and	UHDRS	(p-value:	<2e-
16).	A	statistically	significant	positive	correlation	was	also	observed	between	dystonia	
severity	and	motor	disease	duration	(UHDRS		(Correlation	Coefficient:	0.82,	CI:	0.70-0.89,	p-
value:	9.73e-14),	BFMDRS	(Correlation	Coefficient:	0.84,	CI:	0.74-0.90,	p-value:	4.23e-15)	
(Figure	2),	and	dystonia	severity	and	disease	burden	score	(UHDRS		(Correlation	Coefficient:	
0.62	CI:	(0.42-0.77),	p-value:	1.18e-06),	BFMDRS	(Correlation	Coefficient:	0.57	CI:	(0.35-
0.73),	p-value:	1.34e-05)	(Table	2).	No	significant	relationship	was	seen	between	dystonia	
severity,	CAG	repeat	length	and	age	at	motor	symptom	onset	(Table	2	and	Figure	2).	
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Fifty-one	participants	completed	the	functional	capacity	questionnaires	(UHDRS,	BFMDRS	
and	modified	TWSTRS)	to	determine	the	impact	of	the	movement	disorder	on	day-to-day	
living.	These	demonstrated	a	significant	correlation	(p<0.05)	between	dystonia	severity	and	
functional	capacity,	such	that	more	impaired	daily	functioning	was	observed	with	increasing	
dystonia	severity	(Table	2	and	Supplementary	Figure	1).	We	also	noted	a	significant	
correlation	between	increasing	chorea	severity	and	worsening	functional	capacity,	although	
this	effect	appeared	smaller	than	that	observed	with	dystonia	(BFMDRS	(p=0.008),	UHDFCS	
(p=0.0007),	aTWSTRS	(p=0.0002).	Only	17	patients	(33%)	were	aware	of	their	dystonic	
movements,	with	7	(14%)	individuals	reporting	some	degree	of	distress,	ranging	between	
mild	(3(6%)),	moderate	(3(6%))	and	severe	(1(2%)).		
	
DISCUSSION	
This	study	is	the	first	to	use	systematic	and	standardised	assessment	tools	to	determine	the	
presence,	severity	and	distribution	of	dystonia	in	a	large	cohort	of	patients	with	genetically	
confirmed	HD.	Evidence	of	dystonia	was	documented	in	91%	of	this	cohort,	with	dystonia	
severity	positively	correlated	with	duration	of	motor	symptoms	at	time	of	assessment,	
disease	burden	score	and	increasing	stage	of	HD.	The	upper	limbs	were	the	most	commonly	
and	severely	affected	body	part,	with	reduced	functional	capacity	with	worsening	dystonic	
symptoms.		
	
Previous	studies	have	described	rates	of	up	to	95.2%	of	dystonia	in	HD	cohorts,	reflecting	
the	strong	prevalence	of	dystonia	as	part	of	the	HD	motor	phenotypic	spectrum,	although	
there	are	other	large	cohort	studies	with	no	description	of	dystonia.[17]	Louis	et	al	examined	
42	patients	describing	internal	rotation	of	the	shoulder	(64.3%),	sustained	fist	clenching	
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(47.1%)	and	foot	inversion	(42.9%).	However,	they	reported	only	four	cases	of	
blepharospasm	(9.5%)	and	no	evidence	of	facial	or	laryngeal	dystonia,	compared	to	the	28	
(53%),	35(66%)	and	36(68%)	respectively	seen	in	this	study.[7]	A	possible	explanation	for	this	
lies	in	the	standardised	scales	used	to	assess	this	cohort.	We	sought	to	use	a	dystonia-
specific	tool	(BFMDRS)	to	provide	the	level	of	detail	used	to	assess	primary	dystonic	
disorders.	Here	the	scale	grades	the	severity	and	provoking	factors	in	contrast	to	the	binary	
scale	used	by	Louis	et	al,	hence	providing	greater	scope	in	diagnosis,	although	has	likely	led	
to	an	over	estimation,	particularly	of	laryngeal	and	ocular	involvement.	Previous	reports	
have	also	described	bruxism	in	patients	with	HD	however,	there	was	no	evidence	of	teeth	
grinding	during	the	examination,	and	no	reported	dental	problems	in	this	cohort.[18]		
	
Previous	studies	have	provided	some	conflict	in	those	factors	most	likely	to	impact	the	
presence	and	severity	of	dystonia.	In	this	study	we	found	HD	disease	stage,	motor	disease	
duration	and	disease	burden	score	to	be	related	to	the	severity	of	dystonic	symptoms.	Stage	
of	HD	disease	is	predominantly	determined	by	degree	of	impairment	in	day-to-day	living,	
with	previous	studies	noting	the	same	increase	in	dystonia	severity	with	disease	stage	as	was	
observed	in	this	cohort.[7,	19]	This	idea	is	further	supported	by	results	from	the	multiple	
functional	capacity	assessments	undertaken	in	this	study	(UHDRS,	BFMDRS	and	adapted	
TWSTRS).	We	found	increasing	dystonia	severity	to	be	overwhelmingly	associated	with	
worsening	functional	capacity	using	all	three	scales,	suggesting	that	a	comprehensive	
assessment	of	dystonic	symptoms	is	essential	in	the	symptomatic	management	of	patients	
with	HD.	However,	it	should	also	be	noted	that	these	patients	were	also	of	later	disease	
stage	and	longer	motor	disease	duration,	and	therefore	other	motor	and	non-motor	factors	
are	also	likely	to	impact	their	overall	functional	capacity.	
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A	further	conflict	of	findings	is	seen	with	age	at	motor	symptom	onset	and	CAG	repeat	
length	in	relation	to	dystonia.	This	contrasts	with	findings	from	previous	studies	that	have	
suggested	that	dystonia,	or	‘atypical	movements’	are	more	frequently	observed	in	HD	
patients	with	a	younger	age	at	onset.[2,	8,	20]	However,	both	of	these	latter	studies	focused	
on	patients	with	atypical	patterns	of	presentation,	potentially	suggesting	that	the	findings	
from	this	cohort	are	more	representative	of	the	wider	spectrum	of	motor	phenotype.	These	
findings	are	also	important	in	the	context	of	Juvenile	HD,	cases	of	which	were	not	included	
in	this	study.	Here	the	motor	phenotype	is	considered	to	be	more	bradykinetic	with	more	
pronounced	dystonia.[21]	However,	given	the	specific	pattern	of	motor	symptomatology	it	
may	be	applicable	to	consider	those	with	onset	of	symptoms	<20	years	as	a	distinct	
subgroup.		
	
Treatment	of	movement	disorders	is	often	complicated	in	disorders	such	as	HD	where	
different	forms	may	co-exist	in	the	same	body	part.	Treatment	of	dystonia	is	dependent	on	
its	distribution,	with	botulinum	toxin	injections	used	for	focal	or	segmental	muscle	
involvement,	and	anti-cholinergic	medical	therapy	(e.g.	trihexyphenidyl)	and	tetrabenazine	
for	more	generalised	symptoms.[5,	22]	Of	the	participants	recruited	in	this	study	only	one	
was	receiving	ongoing	botulinum	toxin	treatment	for	cervical	dystonia,	reporting	moderate	
symptomatic	improvement.	Alternative	treatment	options	include	Deep	Brain	Stimulation	
(DBS),	although	a	recent	prospective	pilot	study	(n=6)	found	pallidal	stimulation	to	improve	
dystonic	symptoms	in	only	50%	of	the	cases	examined.[23]	The	potential	benefits	of	
cannabinoids	in	HD	have	also	been	explored,	with	the	American	Academy	of	Neurology	
guidelines	suggesting	that	although	anecdotal	evidence	indicates	improvement	to	non-
Characterisation	of	Dystonia	in	Huntington’s	Disease	
van	de	Zande	et	al	
	
	
12	
chorea	symptoms	in	HD,	randomised	controlled	studies	have	failed	to	demonstrate	a	
significant	symptomatic	improvement.[24]	
	
Symptomatic	treatment	strategies	are	typically	determined	by	the	spectrum	of	patient	
reported	symptoms.	Interestingly,	in	both	this	and	previous	studies,	patients	have	reported	
little	awareness	of	their	dystonic	symptoms.	The	patients	in	this	study	were	able	to	describe	
a	clear	distinction	between	their	dystonic	and	choreic	symptoms	with	none	having	marked	
cognitive	impairment	at	the	time	of	assessment.	Although,	more	advanced	disease	and	
cognitive	impairment	are	likely	to	impact	this	recognition	and	subsequent	reporting.[7]	
However,	treatment	strategies	also	seek	to	target	functional	improvement.	Given	the	
functional	disability	noted	with	increased	dystonia	severity	in	this	study,	an	attempt	at	
treating	dystonic	symptoms	may	result	in	improved	functional	capacity	and	overall	daily	
living.	
	
This	study	is	principally	limited	by	its	cross-sectional	design,	providing	only	a	single	
assessment	and	not	reflecting	daily	and	diurnal	variation.	We	should	also	not	exclude	the	
possibility	that	the	dystonia	observed	may	be	caused	by	factors	other	than	HD.	However,	
past	or	present	use	of	neuroleptic	agents	was	recorded	in	under	a	fifth	of	cases	(10	(18.9%)),	
and	although	a	concurrent	primary	focal	dystonia	remains	possible,	it	would	be	unlikely	to	
explain	the	high	frequency	of	dystonia	observed.	Finally,	frequent	use	of	the	BFMDRS	scale	
in	the	routine	clinical	setting	is	unlikely	given	the	time	required	to	complete	alongside	other	
routine	clinical	measures.	The	UHDRS	dystonia	scale	performed	to	a	similar	high	standard,	
although	it	should	be	noted	that	face,	neck	and	trunk	are	included	in	a	single	score,	and	
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separating	these	into	trunk	and	cranio-cervical	components	may	provide	a	more	robust	
measure,	particularly	in	the	guidance	of	therapeutic	management.	
	
CONCLUSIONS	
This	study	represents	the	largest	single	cohort	of	patients	with	genetically	confirmed	HD	to	
undergo	systematic	assessment	for	dystonia	using	standardised	scales.	We	have	
demonstrated	a	significant	association	of	increased	dystonia	severity	with	increasing	HD	
stage,	disease	burden	score	and	longer	motor	disease	duration.	In	addition,	functional	
capacity	in	day-to-day	living	worsened	with	increasing	dystonia	severity,	reflecting	the	
importance	of	its	inclusion	in	ongoing	management	strategies.	Further	studies	will	be	
needed	to	confirm	these	findings	in	a	larger	cohort,	however,	development	of	the	UHDRS	
Dystonia	rating	scale	to	distinguish	cranio-cervical	and	truncal	regions	may	aid	in	including	
this	as	part	of	routine	clinical	data	collection.		
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FIGURES	
Figure	1:	Relationship	between	HD	disease	stage	and	dystonia	severity	
Legend:	Figure	of	all	scores,	showing	an	increasing	severity	with	a	more	advanced	staged.	
BFMDRS:	Burke	Fahn	Marsden	Dystonia	Rating	Scale,	HD:	Huntington’s	Disease,	UHDRS:	
Unified	Huntington’s	Disease	Rating	Scale.		
	
Figure	2:	Relationship	between	dystonia	severity	and	motor	disease	duration	
Legend:	Scatterplot	with	regression	line	showing	an	increase	in	severity	with	an	increase	of	
motor	disease	duration.	BFMDRS:	Burke	Fahn	Marsden	Dystonia	Rating	Scale,	UHDRS:	
Unified	Huntington’s	Disease	Rating	Scale.	
	
SUPPLEMENTARY	TABLES	
Supplementary	Table	1:	Inter-	and	Intra-Rater	Reliability	Scores	per	Rater	
Legend:	BFMDRS:	Burke	Fahn	Marsden	Dystonia	Rating	Scale,	CI:	Confidence	Interval,	ICC:	
Intra-class	Correlation	Coefficient,	UHDRS:	Unified	Huntington’s	Disease	Rating	Scale	
	
SUPPLEMENTARY	FIGURES	
Supplementary	Figure	1:	Relationship	between	dystonia	severity	and	functional	capacity	
Legend:	Scatterplot	showing	decreased	functional	capacity	with	an	increased	severity	of	
dystonia.	BFMDFRS:	Burke	Fahn	Marsden	Dystonia	Functionality	Rating	Scale,	UHDFCS:	
Unified	Huntington’s	Disease	Functional	Capacity	Scale.	
	
Supplementary	Figure	2:	Mean	and	variance	of	UHDRS	Dystonia	severity	scores	per	rater	
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Legend:	Central	line	indicates	the	mean	score	per	rater,	and	boxplot	whiskers	denote	the	
variance	in	scores.	
	
Supplementary	Figure	3:	Mean	and	variance	of	BFMDRS	Dystonia	severity	scores	per	rater	
Legend:	Central	line	indicates	the	mean	score	per	rater,	and	boxplot	whiskers	denote	the	
variance	in	scores.		
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